Kardigan filed for a U.S. IPO as the company aims to raise capital for three late-stage cardiovascular therapies targeting conditions with limited approved options. The company’s pipeline includes danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for blood pressure management in acute severe hypertension. The filing follows a period in which the public biotech window has been reopening for companies with advanced programs and clearer paths toward commercial adoption. Kardigan’s precision medicine positioning emphasizes molecular targeting and patient-subgroup strategies. For investors and clinicians, the critical items are trial progress and endpoints for each asset, plus whether the company can validate value propositions robust enough for payer acceptance. The IPO proceeds are intended to fund continued development across the late-stage programs, with the company describing significant remaining milestones on its path.